Tetra Bio-Pharma Announces PPP002 Program Update Following Type B Meeting with U.S. FDA
Tetra Bio-Pharma Inc. today announced that it conducted a Type B meeting with the United States Food and Drug Administration (FDA) for its dronabinol AdVersa™ mucoadhesive product, PPP002.